{{expand|time=2016-06-11T11:40:42+00:00}}
{{medical}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 461098524
| IUPAC_name = (3''R'',4''S'')-1-(4-fluorophenyl)-3-[(3''S'')-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
| image = Ezetimibe.svg
| width =
<!--Clinical data-->
| tradename = Zetia
| Drugs.com = {{drugs.com|monograph|ezetimibe}}
| MedlinePlus = a603015
| pregnancy_AU = C
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 35–65%
| protein_bound = >90%
| metabolism = 肠壁，肝脏
| elimination_half-life = 19–30 小时
| excretion = 肾脏11%, 粪便78%
<!--Identifiers-->
| IUPHAR_ligand = 6816
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 163222-33-1
| ATC_prefix = C10
| ATC_suffix = AX09
| PubChem = 150311
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00973
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 132493
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = EOR26LQQ24
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01966
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 49040
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1138
<!--Chemical data-->
| C=24 | H=21 | F=2 | N=1 | O=3
| molecular_weight = 409.4 g·mol<sup>−1</sup>
| SMILES = Fc1ccc(cc1)[C@@H](O)CC[C@H]4C(=O)N(c2ccc(F)cc2)[C@@H]4c3ccc(O)cc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OLNTVTPDXPETLC-XPWALMASSA-N
| melting_point = 164
| melting_high = 166
}}

'''依泽替米贝（{{lang-en|Ezetimibe}}）''' （{{IPAc-en|ɛ|ˈ|z|ɛ|t|i-|m|ɪ|b}}） 是一种用来降低[[血清|血清]][[胆固醇|胆固醇]]浓度的[[药物|药物]]。其作用机理为抑制[[小肠|小肠]]内胆固醇的吸收。当患者对其他抗高脂血症药物不耐受时，依泽替米贝可以单独使用，或者当[[他汀类|他汀类]]药物无法有效控制血脂时与其合用。 <ref>{{cite journal  |vauthors=Stone NJ, Robinson JG, Lichtenstein AH, etal |title=2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines |journal=Circulation |volume=129 |issue=25 Suppl 2 |pages=S1–45 | date=June 2014 |pmid=24222016 |doi=10.1161/01.cir.0000437738.63853.7a |url=}}</ref>

在一些主流的临床医学指南中，依泽替米贝被推荐作为当患者对[[他汀类|他汀类]]药物不耐受，或者单用他汀类药物无法有效降低[[LDL|LDL]]时的推荐二线治疗药物。但是[[美国心脏协会|美国心脏协会]]（AHA）和[[美国心血管学院|美国心血管学院]]（ACC）并不这么推荐。

==引用==
{{Reflist}}

{{MSD}}
{{Lipid modifying agents}}

[[Category:降血脂剂|Category:降血脂剂]]
[[Category:内酰胺|Category:内酰胺]]
[[Category:默克公司|Category:默克公司]]
[[Category:先靈葆雅|Category:先靈葆雅]]
[[Category:有机氟化合物|Category:有机氟化合物]]
[[Category:酚|Category:酚]]